HMB-003 Steps Into the Spotlight Ahead of France

Research evidence excerpt

HMB-003 Steps Into the Spotlight Ahead of France

Quick Note

June 26, 2026 Hemab Therapeutics (COAG)

Rating: HMB-003 Steps Into the Spotlight Ahead of FranceOUTPERFORM

Price:

$27.72 COAG disclosed HMB-003 as its third product candidate and announced multiple

12-Month Price Target: presentations across its pipeline at ISTH 2026 in July. HMB-003 is a peptide

$42.00 plasmin inhibitor being developed as a novel long-acting antifibrinolytic to reduce

bleeding across multiple settings, such as heavy menstrual bleeding and hereditary

hemorrhagic telangiectasia. HMB-003 directly inhibits plasmin at its active site

Analysts and blocks fibrinolysis independently of the plasminogen activation pathway, a

David Nierengarten, Ph.D. mechanistically distinct approach from current antifibrinolytic standard tranexamic

(415) 274-6862 acid, which competitively binds to the lysine-binding sites on both plasminogenDavid.Nierengarten@wedbush.com

and plasmin. In preclinical studies, HMB-003 inhibited fibrinolysis with greaterDennis Pak

(415) 263-6647 potency than tranexamic acid and demonstrated a durable half-life enabling

Dennis.Pak@wedbush.com infrequent subcutaneous dosing. First-in-human studies are planned for 2H26,

Martin Fan, Ph.D. with preparations also underway for a heavy menstrual bleeding study targeted

(213) 688-3404 for 2027. We view the preclinical durability and potency profile as key potential

Martin.Fan@wedbush.com differentiators versus tranexamic acid, which requires frequent oral dosing. In

addition to HMB-003, COAG will present Ph 2 LTE data for sutacimig (FVIIa x TLT-1

bispecific) in Glanzmann thrombasthenia (GT), demonstrating sustained reduction

in ATBR and supporting its planned Ph 3 initiation in 2H26, alongside preclinical data